Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aurinia Pharmaceuticals

7.66
-0.0900-1.16%
Post-market: 7.660.00000.00%16:43 EDT
Volume:943.61K
Turnover:7.28M
Market Cap:1.05B
PE:191.50
High:7.85
Open:7.72
Low:7.65
Close:7.75
Loading ...

Company Profile

Company Name:
Aurinia Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
1993
Employees:
130
Office Location:
#140, 14315 – 118 Avenue,Edmonton,Alberta,Canada
Zip Code:
T5L 4S6
Fax:
250 708 4345
Introduction:
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

Directors

Name
Position
George M. Milne, Jr.
Chairman of the Board
Peter Greenleaf
Director, President and Chief Executive Officer
Daniel G. Billen
Director
David R. W. Jayne
Director
Jill Leversage
Director
Joseph P. Hagan
Director
R. Hector MacKay Dunn
Director
Timothy P. Walbert
Director

Shareholders

Name
Position
Peter Greenleaf
Director, President and Chief Executive Officer
Joe Miller
Chief Financial Officer
M. Maxwell Donley
Executive Vice President, Operations and Strategy
Max Colao
Chief Commercial Officer
Michael R. Martin
Chief Business Officer
Neil Solomons
Chief Medical Officer
Robert B. Huizinga
Executive Vice President, Research
Stephen P. Robertson
Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer